98 related articles for article (PubMed ID: 8694563)
1. Beta 1 integrin expression: a marker of lymphatic metastases in cutaneous malignant melanoma.
Hieken TJ; Ronan SG; Farolan M; Shilkaitis AL; Das Gupta TK
Anticancer Res; 1996; 16(4B):2321-4. PubMed ID: 8694563
[TBL] [Abstract][Full Text] [Related]
2. Expression pattern of the lymphatic and vascular markers VEGFR-3 and CD31 does not predict regional lymph node metastasis in cutaneous melanoma.
Wobser M; Siedel C; Schrama D; Bröcker EB; Becker JC; Vetter-Kauczok CS
Arch Dermatol Res; 2006 Feb; 297(8):352-7. PubMed ID: 16395613
[TBL] [Abstract][Full Text] [Related]
3. Vascular endothelial growth factor-C expression correlates with lymph node localization of human melanoma metastases.
Schietroma C; Cianfarani F; Lacal PM; Odorisio T; Orecchia A; Kanitakis J; D'Atri S; Failla CM; Zambruno G
Cancer; 2003 Aug; 98(4):789-97. PubMed ID: 12910524
[TBL] [Abstract][Full Text] [Related]
4. Regional lymph node dissections in malignant melanoma.
Lawton GP; Ariyan S
Clin Plast Surg; 2000 Jul; 27(3):431-40, ix. PubMed ID: 10941563
[TBL] [Abstract][Full Text] [Related]
5. Beta 1 integrin expression in malignant melanoma predicts occult lymph node metastases.
Hieken TJ; Ronan SG; Farolan M; Shilkaitis AL; Kim DK; Das Gupta TK
Surgery; 1995 Oct; 118(4):669-73; discussion 673-5. PubMed ID: 7570321
[TBL] [Abstract][Full Text] [Related]
6. Lymphatic invasion detected by D2-40/S-100 dual immunohistochemistry does not predict sentinel lymph node status in melanoma.
Petitt M; Allison A; Shimoni T; Uchida T; Raimer S; Kelly B
J Am Acad Dermatol; 2009 Nov; 61(5):819-28. PubMed ID: 19836642
[TBL] [Abstract][Full Text] [Related]
7. Lymphatic invasion identified by monoclonal antibody D2-40, younger age, and ulceration: predictors of sentinel lymph node involvement in primary cutaneous melanoma.
Niakosari F; Kahn HJ; McCready D; Ghazarian D; Rotstein LE; Marks A; Kiss A; From L
Arch Dermatol; 2008 Apr; 144(4):462-7. PubMed ID: 18427039
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of beta1 integrin expression in metastatic melanoma.
Vihinen P; Nikkola J; Vlaykova T; Hahka-Kemppinen M; Talve L; Heino J; Pyrhönen S
Melanoma Res; 2000 Jun; 10(3):243-51. PubMed ID: 10890378
[TBL] [Abstract][Full Text] [Related]
9. Integrin expression in uveal melanoma differs from cutaneous melanoma.
ten Berge PJ; Danen EH; van Muijen GN; Jager MJ; Ruiter DJ
Invest Ophthalmol Vis Sci; 1993 Dec; 34(13):3635-40. PubMed ID: 8258522
[TBL] [Abstract][Full Text] [Related]
10. [Sentinel node biopsy in cutaneous malignant melanoma of the lower extremities].
Kjaer BK; Knudsen MA; Dahlstrøm KK
Ugeskr Laeger; 1999 Apr; 161(16):2358-61. PubMed ID: 10235040
[TBL] [Abstract][Full Text] [Related]
11. [Sentinel lymph nodes in skin melanoma].
Gesuelli GC; Berbellini A; Brianzoni E; Fattori S; Simonacci M; Sigona M; Cardarelli MA
Ann Ital Chir; 2000; 71(2):169-76. PubMed ID: 10920487
[TBL] [Abstract][Full Text] [Related]
12. Surgical management of patients with intermediate thickness melanoma: current role of elective lymph node dissection.
Cole DJ; Baron PL
Semin Oncol; 1996 Dec; 23(6):719-24. PubMed ID: 8970593
[TBL] [Abstract][Full Text] [Related]
13. Elective, therapeutic, and delayed lymph node dissection for malignant melanoma of the head and neck: analysis of 1444 patients from 1970 to 1998.
Fisher SR
Laryngoscope; 2002 Jan; 112(1):99-110. PubMed ID: 11802046
[TBL] [Abstract][Full Text] [Related]
14. Prediction of metastases in melanoma patients with positive sentinel node: histological and molecular approach.
Tsutsumida A; Furukawa H; Hata S; Saito A; Yamamoto Y
J Dermatol; 2007 Jan; 34(1):31-6. PubMed ID: 17204098
[TBL] [Abstract][Full Text] [Related]
15. KBA.62: a useful marker for primary and metastatic melanomas.
Pagès C; Rochaix P; al Saati T; Valmary-Degano S; Boulinguez S; Launay F; Carle P; Lauwers F; Payoux P; Le Guellec S; Brousset P; Lamant L
Hum Pathol; 2008 Aug; 39(8):1136-42. PubMed ID: 18495211
[TBL] [Abstract][Full Text] [Related]
16. Sentinel node biopsy provides more accurate staging than elective lymph node dissection in patients with cutaneous melanoma.
Doubrovsky A; De Wilt JH; Scolyer RA; McCarthy WH; Thompson JF
Ann Surg Oncol; 2004 Sep; 11(9):829-36. PubMed ID: 15313732
[TBL] [Abstract][Full Text] [Related]
17. Impact of false-negative sentinel lymph node biopsy on survival in patients with cutaneous melanoma.
Caracò C; Marone U; Celentano E; Botti G; Mozzillo N
Ann Surg Oncol; 2007 Sep; 14(9):2662-7. PubMed ID: 17597345
[TBL] [Abstract][Full Text] [Related]
18. The survival benefit to patients with positive sentinel node melanoma after completion lymph node dissection may be limited to the subgroup with a primary lesion Breslow thickness greater than 1.0 and less than or equal to 4 mm (pT2-pT3).
Nowecki ZI; Rutkowski P; Michej W
Ann Surg Oncol; 2008 Aug; 15(8):2223-34. PubMed ID: 18506535
[TBL] [Abstract][Full Text] [Related]
19. [Sentinel lymph node dissection in patients with malignant melanoma. Diagnostic and therapeutic standards].
Arens A; Osinga J; Schwipper V; Schober O; Tilkorn H; Liebau J
Chirurg; 2003 Jul; 74(7):665-70. PubMed ID: 12883795
[TBL] [Abstract][Full Text] [Related]
20. Molecular and biochemical testing in stage III melanoma: multimarker reverse transcriptase-polymerase chain reaction assay of lymph fluid after lymph node dissection and preoperative serum lactate dehydrogenase level.
Nowecki ZI; Rutkowski P; Kulik J; Siedlecki JA; Ruka W
Br J Dermatol; 2008 Sep; 159(3):597-605. PubMed ID: 18616789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
